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ance Research Database between 1 January 2000 and 31 December 2008. All
patients received at least two prescriptions for statins and used continuously for at
least 6months during the study periodwere included as the study cohort. Of these,
cases were identified as subjects with the first diagnosis of breast cancer and
matched to randomly selected controls. Hazard ratios were used to estimate the
risk associated with exposure to statin use and breast cancer by Cox proportional
hazards model adjusted for co-morbidities, menopause, diabetes, use of other lip-
id-lowering agents, hormone replacement therapy, cardiovascular drugs and non-
steroidal anti-inflammatory drugs. RESULTS: We identified 99 breast patients
among 17166 statin users from 2001 to 2008. The mean follow-up period was 3.5
years. We found a significant risk of breast cancer among statin users in age-
adjusted (hazard ratio(HR)1.63, 95% confidence interval: (1.301,2.033) , p 0.0001)
and multivariate analysis(HR:1.42, 95% CI: (1.103,1.825),p0.0065). The risk of
breast cancer did not differ significantly in stratified analysis of covariates. How-
ever, a suggestive increased risk of breast cancer among statin users of pre-meno-
pausal, co-administered with cardiovascular drugs and NSAIDs was found.
CONCLUSIONS: This study is likely to support an association between statin use
and breast cancer risk in the population of Chinese.
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DECREASED RISK OF PROSTATE CANCER IN TYPE 2 DIABETES PATIENTS: A
META-ANALYSIS OF COHORT STUDIES
Dipika B1, Gudala K1, Undela K1, Pramil T1, Bhansali A2
1National Institute of Pharmaceutical Education and Research, Mohali, Punjab, India,
2Postgraduate Institute of Medical Education and Research, Mohali, Mohali, India
OBJECTIVES: Emerging evidence suggests that diabetes may increase the risk of
cancers. Available evidence on prostate cancer, however, is conflicting. We there-
fore examined the association between type 2 diabetes and risk of prostate cancer
by conducting a detailed meta-analysis of prospective cohort studies published
regarding this subject. METHODS: PubMed database, CINAHL, EMBASE, and bibli-
ographies of retrieved articles were searched for prospective cohort studies (pub-
lished between 1970 and 2011) investigating the relationship between type 2 dia-
betes and prostate cancer. Pooled risk ratio (RR) was calculated using random-
effects model (DerSimonian and Laird method). Heterogeniety was calculated
using Cochrane’s Q test. To find out heterogeniety we performed subgroup analy-
sis. Sensitivity analysis and cumulative meta-analysis were also done. RESULTS:
Twenty-nine cohort studies involving 5.1 million participants and 92,331 prostate
cancer cases detected a significant inverse association between type 2 diabetes and
risk of prostate cancer (RR 0.87 (95% CI 0.80-0.94)). Sensitivity analysis done by
excluding one outlier further strengthened our negative association (RR 0.82, 95%
CI 0.76-0.84). This association was not substantially modified by Prostate-specific
antigen testing, number of covariates adjustment and adjustment for BMI or obe-
sity. Cumulative meta-analysis showed a change in trend of reporting risk of pros-
tate cancer from positive to negative in type 2 diabetes patients between 1970 and
2011. No evidence of publication bias was observed. CONCLUSIONS: Our meta-
analysis provides strongest evidence supporting that type 2 diabetes is signifi-
cantly inversely associated with risk of developing prostate cancer.
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OBJECTIVES: Studies examining the association between type 2 diabetes and the
risk of breast cancer in women have small sample sizes and inconclusive results.
This study systematically reviews the risk of breast cancer in diabetic women and
compares the risk of breast cancer in Caucasian and Asian women with type 2
diabetes. METHODS: Data for this meta-analysis were extracted from MEDLINE
and EMBASE databases from years 1975 to 2010. Initial search of risk of breast
cancer in women with type 2 diabetes yielded 33 studies. Out of the 33 studies
found in the search, 22 studies met the inclusion criteria with 16 and 6 studies
involving Caucasian and Asian women with a risk of breast cancer, respectively.
RESULTS: The 22 studies analyzed using STATA®SE version10 involved a total of
77,204women (47,083 Caucasians and 30,121Asians).Meta analysis results showed
that overall, women with type 2 diabetes had a 30.5% significantly higher risk of
breast cancer (RR, 1.305; 95% CI, 1.30-1.31). Compared to Western women, Asian
women with type 2 diabetes had 51.9% significantly higher risk of developing
breast cancer (RR, 1.519; 95% CI, 1.508-1.530). CONCLUSIONS: The study shows that
womenwith type 2 diabeteswere likely to be, as a group, at increased risk for breast
cancer, with a relatively higher risk among Asian women. The efficacy of enhance-
ments in glycemic control management, improving insulin sensitivity with exer-
cise and diet control and screening for breast cancer particularly in Asian women
with type 2 diabetes warrants further study.
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OBJECTIVES: A universally accepted staging system for hepatocellular carcinoma
(HCC) has not been adopted. The goal of this work is to assess survival and treat-
ment patterns of HCC patients stratified by the National Comprehensive Cancer
Network (NCCN) staging-guided treatment categories. METHODS: An HCC retro-
spective research registry was developed from linking records in the University of
Utah Enterprise Data Warehouse, the Utah Population Database, and the Hunts-
manCancer Institute Tumor Registry. Patient recordswere included if age 18, at
least one HCC ICD-9 code, documented hepatocellular carcinoma or cholangiocar-
cinoma in the tumor registry, and the presence of informative staging data around
the time of diagnosis. Patients were stratified by the NCCN groupings by chart
review around the time of diagnosis as either: potentially resectable or operable
(RESECT), transplantable (TRANSP), unresectable (UNRESCT), inoperable due to
performance status (INOPER), or having metastatic (METAST) disease. Treatment
patterns and survival were evaluated. RESULTS: A total of 221 patients (161 males,
72.9%) with HCC were identified. At the time of diagnosis 12.7% subjects (n28)
were considered RESCT; 14.9% (n33) TRANSP; 34.8% (n77) UNRESCT; 18.1%
(n40) INOPER, and 17% (n38) METAST. Staging informationwas not available for
5 subjects (2.3%). Kaplan-Meier analysis demonstrated statistically significant dif-
ferences in all groups except between RESCT and TRANSP patients and between
UNRESCT and INOPER patients. Themedian days of survival were 594, 562, 247, 167
and 44 for RESCT, TRANSP, UNRESCT, INOPER, and METAST patients respectively.
RESECT patients most frequently received early resection (61%) and TRANSP pa-
tients had the highest utilization of liver transplant (33%). Utilization of any treat-
ment was low in the METAST (31.6%) and INOPER (60%) groups. CONCLUSIONS:
Treatment patterns were distinct across the NCCN groupings and aligned with
NCCN treatment guidelines. Overall the NCCN groupings predict overall survival.
CANCER - Cost Studies
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OBJECTIVES: Acute Myeloid Leukaemia (AML) can be diagnosed at any age and
accounts for around a third of all leukaemia diagnoses. Treatment, which can be
given with supportive and/or curative intent, is expensive with costly medical
interventions and lengthy hospitalization (often due to complications). Despite
this, little is knownabout its lifetime economic burdenwith few studies attempting
to cost the entire treatment pathway. This investigation aimed to address these
issues by estimating the phase-specific and lifetime pathway costs of a UK cohort
of AML patients. METHODS: The Haematological Malignancy Research Network
(HMRN, www.hmrrn.org), is a population-based study, that has registered newly
diagnosed patients with haematological malignancies in two UK cancer networks.
All adults (18) newly diagnosed with AML from September 2004 to August 2007
were included in the current study (n382). The bottom-up method was used to
cost each treatment, and lifetime costs were calculated by linking the treatment
costs to the treatment pathway. Treatment pathways and medical resource con-
sumption were derived from HMRN and National Hospital Episode Statistics (HES).
Unit costs were determined from various sources, including the British National
Formulary and NHS reference costs. RESULTS: The average lifetime treatment cost
and survival life-years per patient were £40,324(554-247,432) and 5.3 (0.7-68.3)
months, respectively. This cost was largely determined by first-line treatment and
the number of relapses. The major cost-driver throughout all treatment phases
was hospitalization, followed by the costs of drugs and treatment of complication.
CONCLUSIONS:The study demonstrates that costing the treatment pathway using
the bottom-up approach is plausible. In line with existing literature, lifetime costs
of treating AML were found to be high; and it is expected that these findings could
assist decison makers to make informed treatment choices. The costing method
developed in this study could be successfully applied to other diseases with com-
plex treatment pathways.
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OBJECTIVES: For several years, cytotoxic agents have been the backbone of cancer
treatment. There has increasingly, however, been an emergence of new drugs that
are more specific to the target molecule. Some of these novel agents have resulted
in a prolongation of survival and even clinical cures in some cancers. In order to
assess the costs and overall benefits of these new drug therapies, a descriptive
evaluation across seven major tumor types was undertaken. METHODS: A litera-
ture search was conducted from 2000 to 2011 to identify randomized trials of novel
therapies in breast, lung, colorectal, kidney, lymphoma, multiple myeloma and
chronic myelogenous leukemia. Clinical outcomes in terms of progression free
(PFS) and overall survival (OS) benefit were extracted. Economic data in terms of
cost permonth of therapywas obtained from aU.S. cancer clinic. RESULTS:Almost
22 novel therapies were approved across the seven cancers. Four of the 22 (18%)
were used with a curative intent while the remainder were used in the palliative
setting (n18). Ten of these 18 latter agents (56%) also demonstrated an OS benefit.
The median month cost for novel therapies used with a curative intent and those
with a survival benefit in the palliative setting were $5450 and $6450 respectively.
In contrast, the median monthly cost for drugs that did not offer either of these
benefits was $7900. Of the agents identified, imatinib, lenalidomide, rituximab and
trastuzumab provided the greatest magnitude of benefit for both PFS and OS and
would be considered major clinical advances. CONCLUSIONS: Approximately 64%
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of novel cancer drugs approved over the past 11 years are used with a curative
intent or provide a survival benefit in the palliative care setting. However, the
monthly cost for agents not providing these benefits was higher, indicating a dis-
connect between efficacy and cost.
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OBJECTIVES:To predict the potential cost and effects of addingmaleswith females
for HPV vaccination in Thailand. Human Papillomavirus (HPV) is the most com-
monly sexual transmitted virus in the United States. The American Academy of
Pediatrics (AAP) recommends HPV vaccination for adolescent. Many studies show
that HPV vaccination is beneficial in preventing HPV-associated diseases, such as
cervical cancers, cervical intraepithelial neoplasia (CIN), genital warts and others.
In Thailand, cervical cancer is the second most common cancer. The cost and
effects of vaccination in males is generally considered as beneficial as vaccine
coverage of females.METHODS: A basic model of HPV vaccination was developed
based on current literatures to estimate the economic and health effects of HPV-
associated diseases in both males and females in the United States comparing to
populations in Thailand. RESULTS: The baseline vaccination costs per case in USA
and Thailand are 500 USD and 265 USD (9283 baht) respectively. The QALYs gained
per case for both countries are 0.0126 in females and 0.0094 for combined males
and females. Totals for combinedmales and females vaccination is 493,153 QALYs
for USA and 13,957 QALYs for Thailand.CONCLUSIONS:Adding HPV vaccination in
adolescent males in Thailand is certainly more costly, but still beneficial. The po-
tential of health benefits depends more on the female HPV vaccination coverage,
however,males add benefits also. If the coverage rate for females is high, the health
benefits increase. Based on the total population, the benefits can be substantial.
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OBJECTIVES: To assess the cost-effectiveness of introducing CT colonography
(CTC) into the colorectal cancer (CRC) screening program in Japan. METHODS: A
Markovmodel for CRCwas constructed to estimate both the short-term (one-1year)
and the long-term (10-year, 20-year, and lifetime) impact of CTC on costs and
health outcomes using three strategies. Strategy-1was the current screening strat-
egy in Japan, which consists of fecal occult blood test (FOBT) and occult-colonos-
copy (OC). In Strategy-2 and Strategy-3, CTC was added between FOBT and OC. In
Strategy-2, those who were showed positive in FOBT were asked to take CTC (up-
take81.6%). In Strategy-3, only those who rejected OC (36.8%) were asked to take
CTC (uptake50%). ICERs for Strategy-2 and Strategy-3 against Strategy-1 were
calculated. Epidemiological data was obtained mainly from statistics published by
Japanese National Cancer Center. Annual discount rate for both costs and out-
comeswas set as 3%. One-way sensitivities analysis was performed. RESULTS: The
introduction of CTC into the CRC screening program in Japan was proposed to
improve the program effect. For the short-term impact, ICERs for additional CRC
detection were JPY 2,202,000 (1USD80JPY) in Strategy-2 and JPY672,000 in Strate-
gy-3, respectively. For the long-term impact, in the base-case analysis, ICERs for
additional colorectal cancer death avoided were JPY39,660,000 in Strategy-2 and
JPY2,465,000 in Strategy-3, respectively. ICERs for life-year gained were
JPY7,804,000 in Strategy-2 and JPY484,000 in Strategy-3, respectively. During esti-
mating the total lifetime impact, Strategy-3 was considered more cost saving than
Strategy-1. CONCLUSIONS: Although this study did not include the concept of
QALY, the results suggested that CTC may be likely to improve the CRC screening
program in Japan with reasonable costs. Early detection of CRC would improve
patients’ quality of life; moreover, in a long-term perspective, increased costs for
screening may be compensated for decreased costs when treating patients with
advanced CRC.
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OBJECTIVES: To estimate the cost- effectiveness of temsirolimus as a treatment
option in poor risk renal cell carcinoma compared with interferon- and from the
perspective of national health insurance in Taiwan.METHODS:Adecision-analytic
model was developed to estimate the cost effectiveness of temsirolimus. Cost and
the clinical effectiveness data were obtained from published literature and current
reimbursed price published by Bureau of National Health Insurance. All costs and
outcomes were discounted at an annual rate of 3%. The effect of parameter uncer-
tainty on cost-effectiveness was explored through extensive one-way and proba-
bilistic sensitivity analyses. RESULTS: Compared with interferon-a, temsirolimus
treatment resulted in an discounted incremental cost per QALY gained of NT$
4,775,609, based on an estimated mean gain of 0.24 quality- adjusted life years
(QALYs) per patient; and a cost per life-year gain of NT$ 2,512,048. Cost-effective-
ness estimates were most sensitive to changes in hazard ratios for overall survival
between temsirolimus and interferon-a.CONCLUSIONS: In comparisonwith inter-
feron-a, the ICER (NT$4,775,609) for temsirolimus as a treatment in poor risk renal
cell carcinoma, was found to be much higher than the threshold suggested by the
World Health Organization. Therefore, temsirolimus could not be regarded as a
cost-effective option from the National Health Insurance perspective.
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OBJECTIVES: The worldwide incidence of melanoma is increasing rapidly. Two
chemotherapy regimens are used for treatment of Malignant Melanoma: single
agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has
greater cost in Iran so we aimed to do an economic evaluation, to evaluate the
comparative value of treatment of two drugs.METHODS: To compare the efficacy
of these two drugs, a systematic review and meta-analysis were conducted and
published articles, comparing use of single agent Dacarbazine and Temozolomide
in treatment of Malignant Melanoma were reviewed. For this purpose, Pubmed,
Scopous, Web of Science and Cochrane Central Register of Controlled Trials were
searched and the search termswere: “Dacarbazine” and “Temozolomide” and “Ma-
lignantMelanoma”. Datawere collected from inception to 2012. “Response to treat-
ment” includes:” complete response (CR)”,” partial response (PR)” and “stable dis-
ease (SD)”was the key outcomeof interest. The direct cost (drug and administrative
procedures costs) was collected from health provider centers. RESULTS: Themeta-
analysis included 3 RCTS and involved 1314 patients with malignant melanoma.
Approximately half of them were allocated to the TMZ arm and half to the DTIC
arm. Risk differences for CR was -0.01, for PR was 0.03 and for SD was 0.01.
Average cost for one cycle of treatment with TMZ is $1957 and for DTIC is $90 in
Iran. For CR based on economic evaluation grid, TMZ treatment is dominated. The
incremental CE ratio for PR is $62,233 and ICER for SD is $186,700 respectively.
CONCLUSIONS: Considering health outcomes of CR, PR and SD, Temozolomide
treatment for melanoma is not cost effective comparing to Dacarbazine in Iran. It
should be mentioned that generic Dacarbazine is available in Iran but Temozolo-
mide is provided as branded, and availability to generic form of Temozolomide
may affect the results of this economic evaluations.
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OBJECTIVES: To compare the effectiveness and cost-effectiveness of erlotinib ver-
sus gefitinib in first-line treatment of epidermal growth factor receptor (EGFR) ac-
tivating-mutation positive (MuT) non-small cell lung cancer (NSCLC) for Hong
Kong. METHODS: An indirect treatment comparison (ITC), using the Bucher et al
methodology, and a cost-effectiveness assessment (CEA) were performed on the
basis of Asian phase-III randomized controlled trials (RCTs). In total four RCTswere
determined: one for erlotinib (OPTIMAL) and three for gefitinib (IPASS; NEGJSJ,
WJTOG). The CEA model uses a Markov approach that simulates the transition
between the health states: progression-free-survival (PFS), progression and death,
inmonthly cycles over a life-timehorizon. TheWorldHealthOrganization criterion
(incremental cost-effectiveness ratio  3 times GDP/capita; USD 102,582;
,HKD	798,078)was used to rate cost-effectiveness.RESULTS:The best fit of study
characteristics and of prognostic patient characteristics were found between the
OPTIMAL and IPASS trials. Comparing the PFS hazard ratios (HRs) of erlotinib vs.
gefitinib using only these RCTs in an ITC resulted in a statistically significant PFS
difference in favor of erlotinib (ITC HR: 0.33; 95% confidence-intervals: 0.19-0.58;
p0.0001). The CEA model obtained an additional benefit of 0.36 progression-free
life years gained and of 0.23 quality-adjusted life years gained (QALYs) by erlotinib,
whichwas accompanied by additional costs of USD 14,061 (HKD	109,395). The cost
per progression-free life year gained and per QALY gained were USD 39,431
(HKD	306,773) and USD 62,419 (HKD	485,619) comparing erlotinib vs. gefitinib,
respectively.CONCLUSIONS:The ITC of OPTIMAL and IPASS shows that erlotinib is
more efficacious when compared to gefitinib. The CEA for Hong Kong shows that
the costs per progression-free life year gained and the cost per QALY gained by
erlotinib are well within an acceptable range in relation to the survival benefit
obtained. Erlotinib is cost-effective compared to gefitinib in first-line EGFR MuT
NSCLC.
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OBJECTIVES: This study aimed to evaluate the long-term cost-effectiveness of dif-
ferent strategies for self-sampling of human papillomavirus (HPV) testing for cer-
vical cancer screening in Taiwan. METHODS: This study adopts a perspective of
Department of Health in cost-effectiveness analysis to compare a no-screening
strategy with seven different screening strategies. The target populations who
aged over 36 years old and didn’t attend to the regular cervical cancer screening
program over 6 years. The published Markov model of cervical cancer screening in
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